**Conclusion.** This study demonstrated no increased risk of post-operative infection in patients with a positive urinalysis or urine culture with bacteriuria prior to intervention. There was a high use of broad-spectrum antibiotic as a reflex to positive urinalysis alone highlighting an avenue for improved anti-microbial stewardship. More research is needed to guide clinicians on the role of urines and antibiotics prior to non-urgent urological procedures.

**Disclosures. All authors:** No reported disclosures.

**1477. A Randomized Phase 2 Study of Cefepime with the Novel Extended Spectrum β-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP) – OfID 2019:6 (Suppl 2)**

Yebrada Carmeli, MD; Philipp Knechtle, PhD; Jeff Harendberg, BA; Mathias Knecht, MD; Tel Aviv University, Tel Aviv, Israel; 6Allera Therapeutics SAS, Saint Louis, Alsace, France.

**Session:** 157. Urinary Tract Infections

**Friday, October 4, 2019: 12:15 PM**

**Background.** Third-generation cephalosporin (3G)-resistant Enterobacteriaceae has been classified as critical priority pathogens. The novel extended-spectrum β-lactama-

**Methods.** Forty-five patients were enrolled in a randomized, multicenter, double-blind study of hospitalized adults with cUTI/AP. Patients received dosing regi-

**Results.** Three drugs were well tolerated in each cohort, with similar % adverse events and no new or unexpected safety concerns (table). Two discontinuation-

**Conclusion.** Results from this phase 2 study justify advancement to phase 3 studies to evaluate the safety and efficacy of cefepime in patients with cUTI/AP.

**Disclosures. All authors:** No reported disclosures.

**1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS**

Beatrice Guimbao, MD; Paula Peyrani, MD; Chris Webber, MD; Marie Van Der Wielen, MD; Veronique Blanco, MS; John L. Perez, MD; Mark W. Cutler, PhD; Ping Li, PhD; 6Research Institute for Tropical Medicine Muntinlupa City, Philippines, Muntinlupa City, Abra, Philippines; Pfizer, Inc., Collegeville Pennsylvania, Collegeville, Pennsylvania; Pfizer, Ltd. Hurley, UK; 6GloxSmithKline, Waver, Antwerpen, Belgium; 6GSK, Rockville, Maryland; 6Pfizer, Inc., Pearl River, New York

**Session:** 157. Urinary Tract Infections

**Friday, October 4, 2019: 12:15 PM**

**Background.** The quadrivalent meningococcal ACWY polysaccharide tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix) is licensed in various countries to prevent disease caused by meningococcal serogroups A, C, W, and Y. In a previous randomized clinical trial (ClinTrials.gov identifier NCT00100151), subjects received primary MenACWY-TT vaccine recipients with prebooster titers ≥ 1:8 and ≥ 1:128 at year 10 ranged from 71.6%–90.7% and 64.8%–85.2% for all serogroups, respectively, compared with 43.1%–82.4% and 25.5%–76.5% of pri-

**Results.** Of 229 subjects enrolled in this extension study, 169 and 58 subjects in the MenACWY-TT and MenACWY-PS groups, respectively, completed the booster phase. The primary MenACWY-TT recipients with prebooster titers ≥ 1:8 and ≥ 1:128 at year 10 ranged from 71.6%–90.7% and 64.8%–85.2% for all serogroups, respectively, compared with 43.1%–82.4% and 25.5%–76.5% of pri-

**Conclusion.** This Phase IIa single-center study was designed primarily to evaluate plasma and urine pharmacokinetics (PK) of gepotidacin in female participants with acute cystitis. Safety data and clinical and microbiological efficacy of gepotidacin were also assessed as secondary and exploratory endpoints. All participants received oral gepotidacin 1,500 mg BID for 5 days (total of 10 doses) during clinic confinement. Pretreatment and posttreatment PK collections were performed together with safety, efficacy, microbiological, and exploratory assessments throughout the study.

**Results.** Of 229 subjects enrolled in this extension study, 169 and 58 subjects in the MenACWY-TT and MenACWY-PS groups, respectively, completed the booster phase. The primary MenACWY-TT recipients with prebooster titers ≥ 1:8 and ≥ 1:128 at year 10 ranged from 71.6%–90.7% and 64.8%–85.2% for all serogroups, respectively, compared with 43.1%–82.4% and 25.5%–76.5% of pri-

**Conclusion.** This Phase IIa study in the Treatment of Uncomplicated Urinary Tract Infections: J. Scott Overcash, MD, FACEP; Ettiene Dumont, MD; Caroline R. Perry, PhD; Courtney Tiffany, BSc; Nicole Scangarella-Oman, MD; Aparna Raychaudhuri, PhD; Mohammad Hossain, PhD; 6eStudySite, San Diego, California; 6GloxSmithKline, Collegeville, Pennsylvania; 6GSK Pharmaceuticals, Collegeville, Pennsylvania; 6GloxSmithKline Pharmaceuticals, Collegeville, Pennsylvania

**Session:** 157. Urinary Tract Infections

**Friday, October 4, 2019: 12:15 PM**

**Background.** Urinary tract infections (UTIs) are very common, with approximately 11% of women >18 years of age experiencing at least 1 episode of acute cysti-

**Results.** The drugs were well tolerated in each cohort, with similar % adverse events and no new or unexpected safety concerns (table). Two discontinuation-

**Conclusion.** Results from this phase 2 study justify advancement to phase 3 studies to evaluate the safety and efficacy of cefepime in patients with cUTI/AP.

**Disclosures. All authors:** No reported disclosures.

**1479. Clinical Efficacy and Safety Analysis Evaluating Oral Gepotidacin (GSK2140994) From a Phase IIa Study in the Treatment of Uncomplicated Urinary Tract Infections**

Scott Overcash, MD, FACEP; Ettiene Dumont, MD; Caroline R. Perry, PhD; Courtney Tiffany, BSc; Nicole Scangarella-Oman, MD; Aparna Raychaudhuri, PhD; Mohammad Hossain, PhD; 6eStudySite, San Diego, California; 6GloxSmithKline, Collegeville, Pennsylvania; 6GSK Pharmaceuticals, Collegeville, Pennsylvania; 6GloxSmithKline Pharmaceuticals, Collegeville, Pennsylvania

**Session:** 157. Urinary Tract Infections

**Friday, October 4, 2019: 12:15 PM**

**Background.** Urinary tract infections (UTIs) are very common, with approximately 11% of women >18 years of age experiencing at least 1 episode of acute cysti-

**Conclusion.** Results from this phase 2 study justify advancement to phase 3 studies to evaluate the safety and efficacy of cefepime in patients with cUTI/AP.

**Disclosures. All authors:** No reported disclosures.

**1480. Plasma and Urine Pharmacokinetic Analysis of Gepotidacin (GSK2140994) Following BID Oral Dosing in a Phase IIa Study for Treatment of Uncomplicated Urinary Tract Infections**

Eric L. Zimmerman, PhD; Ettiene Dumont, MD; Caroline R. Perry, PhD; Courtney Tiffany, BSc; Nicole Scangarella-Oman, MD; Aparna Raychaudhuri, PhD; Mohammad Hossain, PhD; 6PPD, Richmond, Virginia; 6GloxSmithKline, Collegeville, Pennsylvania; 6GloxSmithKline Pharmaceuticals, Collegeville, Pennsylvania

**Session:** 157. Urinary Tract Infections

**Friday, October 4, 2019: 12:15 PM**